

Informativa resa ai sensi dell'art. 13 del Regolamento UE 2016/679 ed in relazione alle informazioni di cui si entrerà in possesso, ai fini della tutela delle persone e altri soggetti in materia di trattamento di dati personali, si informa quanto segue:

LORENZO DE PAOLI

CURRICULUM VITAE

ed

ELENCO DELLE PUBBLICAZIONI

Lorenzo De Paoli, MD, PhD

Struttura Complessa a Direzione Universitaria Ematologia
Dipartimento di Medicina Clinica e Sperimentale e
Università degli Studi del Piemonte Orientale Amedeo
Avogadro

Via Solaroli, 17
28100 Novara

E-mail: lorenzo.depaoli@med.uniupo.it

Novara, 10 maggio 2023

CURRICULUM VITAE

Luogo e data di nascita: Novara, 10/01/1980

Formazione accademica

- 1999:** Diploma di maturità scientifica (100/100), Liceo Scientifico statale “A. Antonelli”, Novara
- 2003-05:** Allievo interno presso la U.D.A. Ematologia (Responsabile Prof. G. Gaidano), Clinica Medica Generale, Azienda Ospedaliera Maggiore della Carità, Novara
- 2005:** Laurea in Medicina e Chirurgia, Università del Piemonte Orientale A. Avogadro (110/110 lode). Materia: Ematologia. Titolo di tesi: “Identificazione di nuovi marcatori molecolari di prognosi nel Linfoma Diffuso a Grandi Cellule B” (Relatore: Prof. G. Gaidano)
- 2005-09:** Contrattista in Formazione – Specializzando, Scuola di Specializzazione in Ematologia, Università di Milano-Bicocca
- 2009:** Specializzazione in Ematologia presso Università degli Studi di Milano-Bicocca (70/70 con lode). Titolo di tesi: “Trasformazione da “Monoclonal B-cell lymphocytosis a leucemia linfatica cronica: identificazione di predittori clinici e biologici” (Relatore Prof. E.M. Pogliani).
- 2009-13:** Dottorando in Medicina Clinica e Sperimentale, Divisione di Ematologia, Dipartimento di Medicina Traslazionale, Università del Piemonte Orientale A. Avogadro
- 2013:** Dottorato in Medicina Clinica e Sperimentale, Divisione di Ematologia, Dipartimento di Medicina Traslazionale, Università del Piemonte Orientale A. Avogadro. Titolo di tesi: “Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia” (Coordinatore Prof. M. Gariglio, Tutor Prof. G. Gaidano)

Borse di studio e premi

- 2002-05:** Vincitore Borsa di studio Nobile Collegio Caccia
- 2007:** Vincitore Borsa di studio Novara-AIL Onlus / Fondazione Zegna
- 2018:** Premio Luca Morelli Novara-AIL Onlus

Esperienza clinica e professionale

- 2005-09:** Frequenza in qualità di Contrattista in Formazione presso la Struttura Complessa a Direzione Universitaria (S.C.D.U) Ematologia (Dir. Prof. G. Gaidano) della Azienda Ospedaliero-Universitaria Maggiore della Carità di Novara, svolgendo le seguenti attività: i) attività ambulatoriale e di Day Hospital per patologie oncoematologiche ed emoglobinopatie; ii) attività assistenziale in ambito di degenza ordinaria e di trapianto di cellule staminali emopoietiche autologhe; iii) gestione dei disordini

dell'emostasi e della Terapia Anticoagulante Orale; iv) diagnostica morfologica citologica delle malattie del sangue

- 2009-14:** Dirigente Medico a tempo determinato presso la Struttura Complessa a Direzione Universitaria (S.C.D.U.) Ematologia (Dir. Prof. G. Gaidano) dell' Azienda Ospedaliero-Universitaria Maggiore della Carità di Novara
- 2015-2021** Dirigente medico a tempo indeterminato presso la Struttura Complessa a Direzione Universitaria (S.C.D.U.) Ematologia (Dir. Prof. G. Gaidano) dell' Azienda Ospedaliero-Universitaria Maggiore della Carità di Novara
- 2015-2021** Coordinatore GIC (gruppo interdisciplinare cura) delle neoplasie linfoidi, Azienda Ospedaliero-Universitaria Maggiore della Carità di Novara
- 2015-2021** Referente per l'Azienda Ospedaliero-Universitaria Maggiore della Carità di Novara della Rete Oncoematologica del Piemonte per il mieloma multiplo
- 2016-2021** Docente presso la Scuola di Specialità di Radioterapia Università del Piemonte Orientale Amedeo Avogadro Novara per le neoplasie ematologiche
- 2017-2021** Tutor per tirocinio professionalizzante dei Corsi di Studio di Patologia Medica II e di Scienze Oncologiche per la Scuola di Medicina e Chirurgia Università del Piemonte Orientale
- 2017-2021** Consulente/Coordinatore presso Unità di Ematologia Medicina Interna presso Ospedale S. Andrea di Vercelli
- 2018-** Membro della commissione RRMM (mieloma multiplo recidivato refrattario) del Working Group
- 2019-** Tutor presso la Scuola di Specialità di Ematologia Università del Piemonte Orientale Amedeo Avogadro Novara
- 2021-** Dirigente medico a tempo indeterminato presso la Struttura Complessa di Medicina dell'ASL di Vercelli dal 1/9/2021
- 2021-** Direttore di Struttura Semplice di Ematologia presso l'ASL di Vercelli dal 1/10/2021
- 2021-** Rappresentante del Distretto Nord-Ovest di EMN Italy (European Myeloma network)
- 2021-** Coordinatore GIC (gruppo interdisciplinare cura) Ematologia presso l'ASL di Vercelli

Appartenenza a Società Scientifiche e Gruppi di Ricerca di Società Scientifiche

- 2009-:** Società Italiana di Ematologia (SIE)
- 2020-:** European Hematology Association (EHA)

Seminari, relazioni e letture su invito

- *Expert Meeting ECHO “Leucemia Linfatica Cronica”, relatore (Pollenzo, 28/05/2009)*
- *La compliance alla terapia chelante nella Talassemia, relatore (Torino, 16/04/2010).*
- *Progetto AVATAR (Zoledronic Acid Value and Anti Tumor Activity Round Tables).
Presentazione di casi clinici e discussione interattiva (Torino, 05/11/2010)*
- *Piastrinopenie autoimmuni: nuove certezze terapeutiche e prospettive future, relatore (Torino, 10/12/2010)*
- *La gestione dell’ITP cronica: un anno dopo l’arrivo del primo TPO mimetico. Relatore (Torino, 16/12/2011)*
- *“Global Expert Forum on advance in B-Cell malignancies”, relatore (Paris, 27 e 28/02/2015)*
- *“IGs day break: the advent of innovation”, relatore (Roma, 28 and 29/05/2015)*
- *“Mieloma multiplo: il futuro è già qui -Save the date”, relatore (Torino, 17/11/2015)*
- *“Nuove frontiere nella leucemia linfatica cronica”, relatore (Torino 5/2/2016)*
- *XXXI corso di aggiornamento in Nefrologia e dialisi, “Monoclonal Gammopathy of Renal Significance (MGRS)”, relatore (Torino, 10/05/2016)*
- *“Il valore dell’innovazione nella cura del mieloma multiplo”, speaker (Milano 23/05/2016)*
- *“Mieloma multiplo, scenari in evoluzione”, relatore (Torino 20/09/2016)*
- *“ Le terapie target nella LLC: la gestione pratica in uno scenario terapeutico che cambia”:
relatore (8/11/2016)*
- *“Skyforum mieloma multiplo: nuovi scenari terapeutici”:
relatore (Pollenzo, 24/11/2016)*

Lingue straniere

- Inglese

PROSPETTO delle PUBBLICAZIONI

Bibliometria

Lavori su riviste internazionali con Impact Factor	62
Impact Factor cumulative <i>(I.F. secondo ISI 2011)</i>	476
Lavori su riviste internazionali senza Impact Factor	1
Lavori su riviste internazionali con Impact Factor come collaboratore	4

Lecture, relazioni, atti di Congressi Internazionali	2
Lecture, relazioni, atti di Congressi Nazionali	6

Abstract

Abstract su atti di Congressi Internazionali	29
Abstract su atti di Congressi Nazionali	28

PUBBLICAZIONI SCIENTIFICHE

Publicazioni in extenso con Impact Factor (I.F. secondo ISI 2011)

1. Rossi D, Cresta S, Destro T, Vendramin C, Bocchetta S, **De Paoli L**, Cerri M, Lunghi M, Gaidano G.
JAK2V617F IN IDIOPATHIC VENOUS THROMBOEMBOLISM OCCURRING IN THE ABSENCE OF INHERITED OR ACQUIRED THROMBOPHILIA.
Br J Haematol, 138:813-814, 2007 (*Lettera*)
IF: 4.941

2. Rossi D, **De Paoli L**, Franceschetti S, Capello D, Vendramin C, Lunghi M, Conconi A, Magnani C, Gaidano G.
PREVALENCE AND CLINICAL CHARACTERISTICS OF IMMUNE THROMBOCYTOPENIC PURPURA IN A COHORT OF MONOCLONAL GAMMOPATHY OF UNCERTAIN SIGNIFICANCE.
Br J Haematol, 138:249-252, 2007
IF: 4.941

3. Rossi D, Franceschetti S, Capello D, **De Paoli L**, Lunghi M, Conconi A, Gaidano G.
TRANSIENT MONOCLONAL EXPANSION OF CD8+/CD57+ T-CELL LARGE GRANULAR LYMPHOCYTES AFTER PRIMARY CYTOMEGALOVIRUS INFECTION.
Am J Hematol, 82:1103-1105, 2007
IF: 4.671

4. Rossi D, Cerri M, Capello D, Deambrogi C, Rossi FM, Zucchetto A, **De Paoli L**, Cresta S, Rasi S, Spina V, Franceschetti S, Lunghi M, Vendramin C, Bomben R, Ramponi A, Monga G, Conconi A, Magnani C, Gattei V, Gaidano G.
BIOLOGICAL AND CLINICAL RISK FACTORS OF CHRONIC LYMPHOCYTIC LEUKAEMIA TRANSFORMATION TO RICHTER'S SYNDROME.
Br J Haematol, 142:202-215, 2008
IF: 4.941

5. Rossi D, **De Paoli L**, Rossi FM, Cerri M, Deambrogi C, Rasi S, Zucchetto A, Capello D, Gattei V, Gaidano G.
EARLY STAGE CHRONIC LYMPHOCYTIC LEUKAEMIA CARRYING UNMUTATED IGHV GENES IS AT RISK OF RECURRENT INFECTIONS DURING WATCH AND WAIT.
Br J Haematol, 141:734-736, 2008 (*Lettera*)
IF: 4.941

6. Rossi D, Zucchetto A, Rossi FM, Capello D, Cerri M, Deambrogi C, Cresta S, Rasi S, **De Paoli L**, Lobetti Bodoni C, Bulian P, Del Poeta G, Ladetto M, Gattei V, Gaidano G.
CD49d EXPRESSION IS AN INDEPENDENT RISK FACTOR OF PROGRESSIVE DISEASE IN EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA. *Haematologica*, 93:1575-1579, 2008
IF: 6.424

7. Deambrogi C, Cresta S, Cerri M, Rasi S, **De Paoli L**, Ramponi A, Gaidano G, Rossi D.
14q32 TRANSLOCATIONS AND RISK OF RICHTER'S TRANSFORMATION IN CHRONIC LYMPHOCYTIC LEUKAEMIA.
Br J Haematol, 144:131-133, 2009 (*Lettera*)
IF: 4.941

8. Lunghi M, Riccomagno P, **De Paoli L**, Vendramin C, Conconi A, Gaidano G, Rossi D.
MONITORING OF CYTOMEGALOVIRUS REACTIVATION DURING INDUCTION AND NONTRANSPLANT CONSOLIDATION OF ACUTE LEUKEMIA.
Am J Hematol, 84:697-698, 2009 (*Lettera*)
IF: 4.671

9. Rossi D, Cerri M, Deambrogi C, Sozzi E, Cresta S, Rasi S, **De Paoli L**, Spina V, Gattei V, Capello D, Forconi F, Lauria F, Gaidano G.
THE PROGNOSTIC VALUE OF TP53 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA IS INDEPENDENT OF del17p13: IMPLICATIONS FOR OVERALL SURVIVAL AND CHEMOREFRACTORINESS.
Clin Cancer Res, 15:995-1004, 2009
IF: 7.742
10. Rossi D, Lobetti Bodoni C, Genuardi E, Monitillo L, Drandi D, Cerri M, Deambrogi C, Ricca I, Rocci A, Ferrero S, Bernocco E, Capello D, **De Paoli L**, Bergui L, Boi M, Omedè P, Massaia M, Tarella C, Passera R, Boccadoro M, Gaidano G, Ladetto M.
TELOMERE LENGTH IS AN INDEPENDENT PREDICTOR OF SURVIVAL, TREATMENT REQUIREMENT AND RICHTER'S SYNDROME TRANSFORMATION IN CHRONIC LYMPHOCYTIC LEUKEMIA.
Leukemia, 23:1062-1072, 2009
IF: 9.561
11. Rossi D, Rasi S, Franceschetti S, Capello D, Castelli A, **De Paoli L**, Ramponi A, Chiappella A, Pogliani EM, Vitolo U, Kwee I, Bertoni F, Conconi A, Gaidano G.
ANALYSIS OF THE HOST PHARMACOGENETIC BACKGROUND FOR PREDICTION OF OUTCOME AND TOXICITY IN DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH R-CHOP21.
Leukemia, 23:1118-1126, 2009
IF: 9.561
12. Rossi D, Sozzi E, Puma A, **De Paoli L**, Rasi S, Spina V, Gozzetti A, Tassi M, Cencini E, Raspadori D, Pinto V, Bertoni F, Gattei V, Lauria F, Gaidano G, Forconi F.
THE PROGNOSIS OF CLINICAL MONOCLONAL B CELL LYMPHOCYTOSIS DIFFERS FROM PROGNOSIS OF RAI 0 CHRONIC LYMPHOCYTIC LEUKAEMIA AND IS RECAPITULATED BY BIOLOGICAL RISK FACTORS.
Br J Haematol, 146:64-75, 2009
IF: 4.941
13. Rossi D, Spina V, Cerri M, Rasi S, Deambrogi C, **De Paoli L**, Laurenti L, Maffei R, Forconi F, Bertoni F, Zucca E, Agostinelli C, Cabras A, Lucioni M, Martini M, Magni M, Deaglio S, Ladetto M, Nomdedeu JF, Besson C, Ramponi A, Canzonieri V, Paulli M, Marasca R, Larocca LM, Carbone A, Pileri SA, Gattei V, Gaidano G.
STEREOTYPED B-CELL RECEPTOR IS AN INDEPENDENT RISK FACTOR OF CHRONIC LYMPHOCYTIC LEUKEMIA TRANSFORMATION TO RICHTER SYNDROME.
Clin Cancer Res, 15:4415-4422, 2009
IF: 7.742
14. Francesca Rossi I, Maria Teresa Petrucci, Andrea Guffanti, Luigi Marcheselli, Davide Rossi, Vincenzo Callea, Federico Vincenzo, Marianna De Muro, Alessandra Baraldi, Oreste Villani, Pellegrino Musto, Andrea Bacigalupo, Gianluca Gaidano, Giuseppe Avvisati, Maria Goldaniga, Lorenzo DePaoli, Luca Baldini

Proposal and validation of prognostic scoring systems for IgG and IgA monoclonal gammopathies of undetermined significance
Clin cancer Res, 2009 Jul 1;15(13):4439-45. doi: 10.1158/1078-0432.CCR-08-3150. Epub 2009 Jun 9.
IF: 13.8

15. Deambrogi C, **De Paoli L**, Fangazio M, Cresta S, Rasi S, Spina V, Gattei V, Gaidano G, Rossi D.
ANALYSIS OF THE REL, BCL11A AND MYCN PROTO-ONCOGENES BELONGING TO THE 2p AMPLICON IN CHRONIC LYMPHOCYTIC LEUKEMIA.
Am J Hematol, 85:541-544, 2010 (*Lettera*)
IF: 4.671

16. Lunghi M, Casorzo L, **De Paoli L**, Riccomagno P, Rossi D, Gaidano G.
DERIVATIVE (1)t(1;16)(p11;p11.1) IN MYELOYDYSPLASTIC SYNDROME: A CASE REPORT AND REVIEW OF THE LITERATURE.
Cancer Genet Cytogenet, 196:89-92, 2010
IF: 1.389

17. Rossi D, Deambrogi C, Monti S, Cresta S, **De Paoli L**, Fangazio M, Giardini I, Brnasconi P, Gaidano G.
BCL3 TRANSLOCATION IN CLL WITH TYPICAL PHENOTYPE: ASSESMENT OF FREQUENCY, ASSOCIATION WITH CYTOGENETIC SUBGROUPS, AND PROGNOSTIC SIGNIFICANCE.
Br J Haematol, 150:702-704, 2010 (*Lettera*)
IF: 4.941

18. Rossi D, Fangazio M, **De Paoli L**, Puma A, Riccomagno P, Pinto V, Zigrossi P, Ramponi A, Monga G, Gaidano G.
BETA-2-MICROGLOBULIN IS AN INDEPENDENT PREDICTOR OF PROGRESSION IN ASYMPTOMATIC MULTIPLE MYELOMA.
Cancer, 116:2188-2200, 2010
IF: 4.771

19. Rossi D, Lobetti Bodoni C, Zucchetto A, Rasi S, **De Paoli L**, Fangazio M, Rossi FM, Ladetto M, Gattei V, Gaidano G.
LOW CD49d EXPRESSION AND LONG TELOMERE IDENTIFY A CHRONIC LYMPHOCYTIC LEUKEMIA SUBSET WITH HIGHLY FAVOURABLE OUTCOME.
Am J Hematol, 85:619-622, 2010 (*Lettera*)
IF: 4.671

20. Fangazio M*, **De Paoli L***, Rossi D, Gaidano G.
PREDICTIVE MARKERS AND DRIVING FACTORS BEHIND RICHTER SYNDROME DEVELOPMENT.
Expert Rev Anticancer Ther, 11:433-442, 2011 (* equal contribution)
IF: 2.652

21. Rasi S, Bruscazzin A, Rinaldi A, Cresta S, Fangazio M, **De Paoli L**, Monti S, Gargiulo E, Kwee I, Foà R, Bertoni F, Gaidano G, Rossi D.
SALIVA IS A RELIABLE AND PRACTICAL SOURCE OF GERMLINE DNA FOR GENOME-WIDE STUDIES IN CHRONIC LYMPHOCYTIC LEUKEMIA.
Leuk Res, 35:1419-1422, 2011
IF: 2.923
22. Rasi S, Spina V, Bruscazzin A, Vaisitti T, Tripodo C, Forconi F, **De Paoli L**, Fangazio M, Sozzi E, Cencini E, Laurenti L, Marasca R, Visco C, Xu-Monette ZY, Gattei V, Young KH, Malavasi F, Deaglio S, Gaidano G, Rossi D.
A VARIANT OF THE LRP4 GENE AFFECTS THE RISK OF CHRONIC LYMPHOCYTIC LEUKAEMIA TRANSFORMATION TO RICHTER SYNDROME.
Br J Haematol, 152:284-294, 2011
IF: 4.941
23. Rossi D, Rasi S, Di Rocco A, Fabbri A, Forconi F, Gloghini A, Bruscazzin A, Franceschetti S, Fangazio M, **De Paoli L**, Bruna R, Capello D, Chiappella A, Lobetti Bodoni C, Giachelia M, Tisi MC, Pogliani EM, Lauria F, Ladetto M, Hohaus S, Martelli M, Vitolo U, Carbone A, Foà R, Gaidano G.
THE HOST GENETIC BACKGROUND OF DNA REPAIR MECHANISMS IS AN INDEPENDENT PREDICTOR OF SURVIVAL IN DIFFUSE LARGE B-CELL LYMPHOMA.
Blood, 117:2405-2413, 2011
IF: 9.898
24. Rossi D, Rasi S, Fabbri G, Spina V, Fangazio M, Forconi F, Marasca R, Laurenti R, Bruscazzin A, Cerri M, Monti S, Cresta S, Famà R, **De Paoli L**, Bulian P, Gattei V, Guarini A, Deraglio S, Capello D, Rabadan R, Pasqualucci L, Dalla-Favera R, Foà R, Gaidano G.
MUTATIONS OF NOTCH1 ARE AN INDEPENDENT PREDICTOR OF SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA.
Blood, 119:521-529, 2012
IF 9.898
25. Falco P, Cavallo F, Larocca A, Rossi D, Guglielmelli T, Rocci A, Grasso M, Siez ML, **De Paoli L**, Oliva S, Molica S, Mina R, Gay F, Benevolo G, Musto P, Omedè P, Freilone R, Bringhen S, Carella AM, Gaidano G, Boccadoro M, Palumbo A.
LENALIDOMIDE-PREDNISONE INDUCTION FOLLOWED BY LENALIDOMIDE-MELPHALAN-PREDNISONE CONSOLIDATION AND LENALIDOMIDE-PREDNISONE MAINTENANCE IN NEWLY DIAGNOSED ELDERLY UNFIT MYELOMA PATIENTS.
Leukemia, 27 (3): 695-701, 2013
IF 9.561

26. De Paoli L, Cerri M, Monti S, Rasi S, Spina V, Bruscazzin A, Greco M, Ciardullo C, Famà R, Cresta S, Maffei R, Ladetto M, Martini M, Laurenti L, Forconi F, Marasca R, Larocca LM, Bertoni F, Gaidano G, Rossi D.

MGA, A SUPPRESSOR OF MYC, IS RECURRENTLY INACTIVATED IN HIGH RISK CHRONIC LYMPHOCYTIC LEUKEMIA.

Leuk Lymphoma, 54 (5): 1087-90, 2013

IF 2.580

27. Montillo M, Tedeschi A, Gaidano G, Coscia M, Belsito Petrizzi V, Orlandi E, Cascavilla N, Ghia P, Motta M, Gallamini A, Frustaci AM, Rossi D, **De Paoli L**, Nichelatti M, Morra E, Massaia M.

BENDAMUSTINE AND SUBCUTANEOUS ALEMTUZUMAB COMBINATION IS AN EFFECTIVE TREATMENT IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS.

Haematologica, pii: haematol.2014.106740

IF: 6.424

28. Rossi D, Khiabani H, Spina V, Ciardullo C, Bruscazzin A, Famà R, Rasi S, Monti S, Deambrogi C, **De Paoli L**, Wang J, Gattei V, Guarini A, Foà R, Rabadan R, Gaidano G.

CLINICAL IMPACT OF SMALL TP53 MUTATED SUBCLONES IN CHRONIC LYMPHOCYTIC LEUKEMIA.

Blood, 123:2139-47, 2014

IF 9.898

29. Peretti A, Borgogna C, Rossi D, **De Paoli L**, Bawadekar M, Zavattaro E, Boldorini R, De Andrea M, Gaidano G, Gariglio M.

ANALYSIS OF HUMAN BETA PAPILLOMAVIRUS AND MERKEL CELL POLYOMAVIRUS INFECTION IN SKIN LESIONS AND EYEBROW HAIR BULBS FROM A COHORT OF CHRONIC LYMPHOCYTIC LEUKAEMIA PATIENTS.

Br J Dermatol, 2014, doi 10.1111/bjd. 13215

IF 3.759

30. Rossi D, Terzi-di-Bergamo L, **De Paoli L**, Cerri M, Ghilardi G, Chiarenza A, Bulian P, Visco C, Mauro FR, Morabito F, Cortelezzi A, Zaja F, Forconi F, Laurenti L, Del Giudice I, Gentile M, Vincelli I, Motta M, Coscia M, Rigolin GM, Tedeschi A, Neri A, Marasca R, Perbellini O, Moreno C, Del Poeta G, Massaia M, Zinzani PL, Montillo M, Cuneo A, Gattei V, Foà R, Gaidano G.

MOLECULAR PREDICTION OF DURABLE REMISSION AFTER FIRST LINE FLUDARABINE-CYCLOPHOSPHAMIDE-RITUXIMAB IN CHRONIC LYMPHOCYTIC LEUKEMIA

Blood, 2015, pii: blood-2015-05-647925

IF 9.898

- 31.** Tedeschi A, Rossi D, Motta M, Quaresmini G, Rossi M, Coscia M, Anastasia A, Rossini F, Cortelezzi A, Nador G, Scarfò L, Cairoli R, Frustaci AM, Dalceglio D, Picardi P, **De Paoli L**, Orlandi E, Rambaldi A, Massaia M, Gaidano G, Montillo M; Rete Ematologica Lombarda (REL)–CLL workgroup.
A PHASE II MULTI-CENTER TRIAL OF PENTOSTATIN PLUS CYCLOPHOSPHAMIDE WITH OFATUMUMAB IN OLDER PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS.
Haematologica, 2015, doi: 10.3324/haematol.2015.132035. Epub 2015 Aug 20
IF 6.424
- 32.** Magarotto V, Bringhen S, Offidani M, Benevolo G, Patriarca F, Mina R, Falcone AP, **De Paoli L**, Pietrantuono G, Gentili S, Musolino C, Giuliani N, Bernardini A, Conticello C, Pulini S, Ciccone G, Maisnar V, Ruggeri M, Zambello R, Guglielmelli T, Ledda A, Liberati AM, Montefusco V, Hajek R, Boccadoro M, Palumbo A.
TRIPLET VS DOUBLET LENALIDOMIDE-CONTAINING REGIMENS FOR THE TREATMENT OF ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA.
Blood, 2016 pii: blood-2015-08-662627
IF 9.898
- 33.** Rasi S, Khiabani H, Ciardullo C, Terzi-di-Bergamo L, Monti S, Spina V, Brusca A, Cerri M, Deambrogi C, Martuscelli L, Biasi A, Spaccarotella E, **De Paoli L**, Gattei V, Foa' R, Rabadan R, Gaidano G, Rossi D.
CLINICAL IMPACT OF SMALL SUBCLONES HARBORING NOTCH1, SF3B1 OR BIRC3 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA.
Haematologica, 2016 Jan 27. pii: haematol.2015.136051
IF 6.424
- 34.** Larocca A, Bringhen S, Teresa Petrucci M, Oliva S, Pia Falcone A, Caravita T, Villani O, Benevolo G, Liberati AM, Morabito F, Montefusco V, Passera R, De Rosa L, Omedé P, Vincelli ID, Spada S, Carella AM, Ponticelli E, Derudas D, Genuardi M, Guglielmelli T, Nozzoli C, Aghemo E, **De Paoli L**, Conticello C, Musolino C, Offidani M, Boccadoro M, Sonneveld P, Palumbo A
A PHASE 2 STUDY OF THREE LOW-DOSE INTENSITY SUBCUTANEOUS BORTEZOMIB REGIMENS IN ELDERLY FRAIL PATIENTS WITH UNTREATED MULTIPLE MYELOMA
Leukemia, 2016 Feb 22. doi: 10.1038/leu.2016.36.
IF 9.561
- 35.** **De Paoli L**, Gaidano G.
CHRONIC LYMPHOCYTIC LEUKAEMIA: A STEP AHEAD IN THE JOURNEY TOWARD ERADICATION
Lancet Oncology, 2017 Jan doi: 10.1016/S1470-2045(17)30017-7
IF 26.509
- 36.** Ghione P, Genuardi E, Rossi D, Drandi D, Mantoan B, Barbero D, Bernocco E, Montillo L, Cerri M, Ruggeri M, Omede P, Deambrogi C, **De Paoli L**, Passera R, Coscia M, Cavallo F, Massaia M, Boccadoro M, Gaidano G, Ladetto M, Ferrero S.
Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow-up
Br J Haematol. 2018 Jun;181(5):693-695. doi: 10.1111/bjh.14681. Epub 2017 Apr 2.

IF: 4.941

37. Bringhen S, D'Agostino M, **De Paoli L**, Montefusco V, Liberati AM, Galieni P, Grammatico S, Muccio VE, Esma F, De Angelis C, Musto P, Ballanti S, Offidani M, Petrucci MT, Gaidano G, Corradini P, Palumbo A, Sonneveld P, Boccadoro M.

Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma.

Leukemia. 2018 Apr;32(4):979-985. doi: 10.1038/leu.2017.327. Epub 2017 Nov 16

IF: 9.561

38. Bringhen S, Mina R, Cafro AM, Liberati AM, Spada S, Belotti A, Gaidano G, Patriarca F, Troia R, Fanin R, **De Paoli L**, Rossi G, Lombardo A, Bertazzoni P, Palumbo A, Sonneveld P, Boccadoro M.

Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study.

Leukemia. 2018 Aug;32(8):1803-1807. doi: 10.1038/s41375-018-0024-1. Epub 2018 Jan 30.

IF: 9.561

39. Cerrato C, Di Raimondo F, **De Paoli L**, Spada S, Patriarca F, Crippa C, Mina R, Guglielmelli T, Ben-Yehuda D, Oddolo D, Nozzoli C, Angelucci E, Cascavilla N, Rizzi R, Rocco S, Baldini L, Ponticelli E, Marcatti M, Cangialosi C, Caravita T, Benevolo G, Ria R, Nagler A, Musto P, Tacchetti P, Corradini P, Offidani M, Palumbo A, Petrucci MT, Boccadoro M, Gay F.

Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis.

J Cancer Res Clin Oncol. 2018 Jul;144(7):1357-1366. doi: 10.1007/s00432-018-2641-5. Epub 2018 Apr 19

IF: 3.282

40. Mina R, Petrucci MT, Corradini P, Spada S, Patriarca F, Cerrato C, **De Paoli L**, Pescosta N, Ria R, Malfitano A, Musto P, Baldini L, Guglielmelli T, Gamberi B, Mannina D, Benevolo G, Zambello R, Falcone AP, Palumbo A, Nagler A, Calafiore V, Hájek R, Spencer A, Boccadoro M, Bringhen S.

Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma in complete Response

Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):533-540. doi: 10.1016/j.clml.2018.05.019. Epub 2018 May 28

IF: 2.308

41. D'Agostino M, **De Paoli L**, Conticello C, Offidani M, Ria R, Petrucci MT, Spada S, Marcatti M, Catalano L, Gilestro M, Guglielmelli T, Baldini L, Gamberi B, Rizzi R, De Sabbata G, Di Renzo N, Patriarca F, Pezzatti S, Siniscalchi A, Ribolla R, Palumbo A, Montefusco V, Nagler A, Boccadoro M, Gay F.

Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials.

Crit Rev Oncol Hematol. 2018 Dec;132:9-16. doi: 10.1016/j.critrevonc.2018.09.008. Epub 2018 Sep 14

IF: 5.012

42. Saltarella I, Morabito F, Giuliani N, Terragna C, Omedè P, Palumbo A, Bringhen S, **De Paoli L**, Martino E, Larocca A, Offidani M, Patriarca F, Nozzoli C, Guglielmelli T, Benevolo G, Callea V, Baldini L, Grasso M, Leonardi G, Rizzo M, Falcone AP, Gottardi D, Montefusco V, Musto P, Petrucci MT, Dammacco F, Boccadoro M, Vacca A, Ria R.

Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial.

J Hematol Oncol. 2019 Jan 9;12(1):4. doi: 10.1186/s13045-018-0691-4

IF: 8.731

43. Montefusco V, Gay F, Spada S, **De Paoli L**, Di Raimondo F, Ribolla R, Musolino C, Patriarca F, Musto P, Galieni P, Ballanti S, Nozzoli C, Cascavilla N, Ben-Yehuda D, Nagler A, Hajek R, Offidani M, Liberati AM, Sonneveld P, Cavo M, Corradini P, Boccadoro M.

Outcome of paraosseus extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs

Haematologica. 2019 Jun 20. pii: haematol.2019.219139. doi: 10.3324/haematol.2019.219139

IF: 6.424

44. Larocca A, Mina R, Offidani M, Liberati AM, Ledda A, Patriarca F, Evangelista A, Spada S, Benevolo G, Oddolo D, Innao V, Cangialosi C, Bernardini A, Musto P, Amico V, Fraticelli V, Paris L, Giuliani N, Falcone AP, Zambello R, **De Paoli L**, Romano A, Palumbo A, Montefusco V, Hajek R, Boccadoro M, Bringhen S.

First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials

Haematologica. 2019 Jun 27. pii: haematol.2019.220657. doi: 10.3324/haematol.2019.220657

IF: 6.424

45. Diop F, Moia R, Favini C, Spaccarotella E, **De Paoli L**, Brusca A, Spina V, Terzi-di-Bergamo L, Arruga F, Tarantelli C, Deambrogi C, Rasi S, Adhinaveni R, Patriarca A, Favini S, Sagiraju S, Jabangwe C, Kodipad AA, Peroni D, Mauro FR, Del Giudice I, Forconi F, Cortelezzi A, Zaja F, Bomben R, Rossi FM, Visco C, Chiarenza A, Rigolin GM, Marasca R, Coscia M, Perbellini O, Tedeschi A, Laurenti L, Motta M, Donaldson D, Weir P, Mills K, Thornton P, Lawless S, Bertoni F, Del Poeta G, Cuneo A, Follenzi A, Gattei V, Boldorini RL, Catherwood M, Deaglio S, Foà R, Gaidano G, Rossi D.

Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia.

Haematologica. 2019 Aug 1. pii: haematol.2019.219550. doi: 10.3324/haematol.2019.219550.

IF: 6.424

46. Moia R, Boggio E, Gigliotti L, Crisà E, De Paoli L, Margiotta Casaluci G, Rolla R, Patriarca A, Gaidano G, Dianzani U, Bruna R.

Anti-rasburicase antibodies induce clinical refractoriness by inhibiting the enzyme catalytic activity.

Hematol Oncol. 2020 Apr;38(2):204-206. doi: 10.1002/hon.2700. Epub 2020 Jan 27.

IF: 2.832

47. Condoluci A, Terzi di Bergamo L, Langerbeins P, Hoehstetter MA, Herling CD, **De Paoli L**, Delgado J, Rabe KG, Gentile M, Doubek M, Mauro FR, Chiodin G, Mattsson M, Bahlo J, Cutrona G, Kotaskova J, Deambrogi C, Smedby KE, Spina V, Brusca A, Wu W, Moia R, Bianchi E, Gerber B, Zucca E, Gillessen S, Ghielmini M, Cavalli F, Stussi G, Hess MA, Baumann TS, Neri A, Ferrarini M, Rosenquist R, Forconi F, Foà R, Pospisilova S, Morabito F,

Stilgenbauer S, Döhner H, Parikh SA, Wierda WG, Montserrat E, Gaidano G, Hallek M, Rossi D.

International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. *Blood*. 2020 May 21;135(21):1859-1869. doi: 10.1182/blood.2019003453.

IF: 17.543

48. Mina R, Joseph NS, Gay F, Kastritis E, Petrucci MT, Kaufman JL, Montefusco V, Gavriatopoulou M, Patriarca F, Omedé P, Boise LH, Roussou M, Giuliani N, Oliva S, Offidani M, Belotti A, Jaye DL, **De Paoli L**, Terpos E, Lonial S, Boccadoro M, Nooka AK, Dimopoulos MA

Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents.

Blood Cancer J. 2020 Apr 14;10(4):40. doi: 10.1038/s41408-020-0307-4.

IF: 8.211

49. Cuneo A, Scarfò L, Reda G, Varettoni M, Quaglia FM, Marchetti M, **De Paoli L**, Re F, Pietrasanta D, Rigolin GM, Orsucci L, Ibatici A, Gattei V, Mauro FR, Trentin L, Laurenti L, Marasca R, Foà R

Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report.

Blood. 2020 Aug 6;136(6):763-766. doi: 10.1182/blood.2020006854.

IF: 17.543

50. Porrazzo M, Nicolai E, Riminucci M, Vitale C, Coscia M, **De Paoli L**, Rago A, Buscicchio G, Maestrini G, Ligia S, Di Prima A, Corsi A, Caronna R, Gaidano G, Mauro FR.

Prognostic Significance of PET/CT in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Chemoimmunotherapy.

Cancers (Basel). 2020 Jul 3;12(7):1773. doi: 10.3390/cancers12071773.

IF: 6.126

51. Scarfò L, Chatzikonstantinou T, Rigolin GM, Quaresmini G, Motta M, Vitale C, Garcia-Marco JA, Hernández-Rivas JÁ, Mirás F, Baile M, Marquet J, Niemann CU, Reda G, Munir T, Gimeno E, Marchetti M, Quaglia FM, Varettoni M, Delgado J, Iyengar S, Janssens A, Marasca R, Ferrari A, Cuéllar-García C, Itchaki G, Špaček M, **De Paoli L**, Laurenti L, Levin MD, Lista E, Mauro FR, Šimkovič M, Van Der Spek E, Vandenberghe E, Trentin L, Wasik-Szczepanek E, Ruchlemer R, Bron D, De Paolis MR, Del Poeta G, Farina L, Foglietta M, Gentile M, Herishanu Y, Herold T, Jaksic O, Kater AP, Kersting S, Malerba L, Orsucci L, Popov VM, Sportoletti P, Yassin M, Pocali B, Barna G, Chiarenza A, Dos Santos G, Nikitin E, Andres M, Dimou M, Doubek M, Enrico A, Hakobyan Y, Kalashnikova O, Ortiz Pareja M, Papaioannou M, Rossi D, Shah N, Shrestha A, Stanca O, Stavroyianni N, Strugov V, Tam C, Zdrenghea M, Coscia M, Stamatopoulos K, Rossi G, Rambaldi A, Montserrat E, Foà R, Cuneo A, Ghia P.

COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus.

Leukemia. 2020 Sep;34(9):2354-2363. doi: 10.1038/s41375-020-0959-x. Epub 2020 Jul 9.

IF: 9.561

52. Oliva S, **De Paoli L**, Ruggeri M, Caltagirone S, Troia R, Oddolo D, D'Agostino M, Gilestro M, Mina R, Saraci E, Margiotta Casaluci G, Genuardi E, Bringham S, Boccadoro M, Omedé P
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma

Ann Hematol. 2021 Feb;100(2):437-443. doi: 10.1007/s00277-020-04384-w. Epub 2021 Jan 3

IF: 2.904

53. Vitale C, Salvetti C, Griggio V, Porrizzo M, Schiattone L, Zamproga G, Visentin A, Vassallo F, Cassin R, Rigolin GM, Murru R, Laurenti L, Rivela P, Marchetti M, Pennese E, Gentile M, Boccellato E, Perutelli F, Montalbano MC, **De Paoli L**, Reda G, Orsucci L, Trentin L, Cuneo A, Tedeschi A, Scarfò L, Gaidano G, Mauro FR, Foà R, Boccadoro M, Coscia M. Pre-existing and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs

Blood. 2021 Mar 2;blood.2020008201. doi: 10.1182/blood.2020008201. Online ahead of print.

IF: 17.543

54. Mauro FR, Giannarelli D, Visentin A, Reda G, Sportoletti P, Frustaci AM, Chiarenza A, Ciolli S, Vitale C, Laurenti L, De Paoli L, Murru R, Gentile M, Rigolin GM, Levato L, Giordano A, Del Poeta G, Stelitano C, Ielo C, Noto A, Guarente V, Molica S, Coscia M, Tedeschi A, Gaidano G, Cuneo A, Foà R, Martelli M, Girmenia C, Gentile G, Trentin L. Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

Cancers. 2021 Jun 29;13(13):3240

IF 6.639

55. Cuneo A, Rigolin GM, Coscia M, Quaresmini G, Scarfò L, Mauro FR, Motta M, Quaglia FM, Trentin L, Ferrario A, Laurenti L, Reda G, Ferrari A, Pietrasanta D, Sportoletti P, Re F, De Paoli L, Foglietta M, Giordano A, Marchetti M, Farina L, Del Poeta G, Varettoni M, Chiurazzi F, Marasca R, Malerba L, Ibatici A, Tisi MC, Stefoni V, Leone M, Baratè C, Olivieri J, Murru R, Gentile M, Sanna A, Gozzetti A, Gattei V, Gottardi D, Derenzini E, Levato L, Orsucci L, Penna G, Chiarenza A, Foà R.

Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report

Hematol Oncol 2021 Oct;39(4):570-574

IF 5.271

56. Moia R, Favini C, Ferri V, Forestieri G, Terzi Di Bergamo L, Schipani M, Sagiraju S, Andorno A, Rasi S, Adhinaveni R, Talotta D, Al Essa W, De Paoli L, Margiotta Casaluci G, Patriarca A, Boldorini RL, Rossi D, Gaidano G.

Multiregional sequencing and circulating tumour DNA analysis provide complementary approaches for comprehensive disease profiling of small lymphocytic lymphoma

Br J Haematol 2021 Oct;195(1):108-112.

IF 6.998

57. Chatzikonstantinou T, Kapetanakis A, Scarfò L, Karakatsoulis G, Allsup D, Cabrero AA, Andres M, Antic D, Baile M, Baliakas P, Bron D, Capasso A, Chatzileontiadou S, Cordoba R, Correa JG, Cuéllar-García C, De Paoli L, De Paolis MR, Del Poeta G, Demosthenous C, Dimou M, Donaldson D, Doubek M, Efstathopoulou M, Eichhorst B, El-Ashwah S, Enrico A, Espinet B, Farina L, Ferrari A, Foglietta M, Frederiksen H, Fürstenau M, García-Marco JA, García-Serra R, Gentile M, Gimeno E, Glenthøj A, Gomes da Silva M, Gutwein O, Hakobyan YK, Herishanu Y, Hernández-Rivas JÁ, Herold T, Innocenti I, Itchaki G, Jaksic O, Janssens A, Kalashnikova OB, Kalicińska E, Karlsson LK, Kater AP, Kersting S, Labrador J, Lad D, Laurenti L, Levin MD, Lista E, Lopez-Garcia A, Malerba L, Marasca R, Marchetti M, Marquet J, Mattsson M, Mauro FR, Milosevic I, Mirás F, Morawska M, Motta M, Munir T, Murru R,

Niemann CU, Rodrigues RN, Olivieri J, Orsucci L, Papaioannou M, Pavlovsky MA, Piskunova I, Popov VM, Quaglia FM, Quaresmini G, Qvist K, Reda G, Rigolin GM, Ruchlemer R, Saghumyan G, Shrestha A, Šimkovič M, Špaček M, Sportoletti P, Stanca O, Stavroyianni N, Tadmor T, Te Raa D, Tonino SH, Trentin L, Van Der Spek E, van Gelder M, van Kampen R, Varettoni M, Visentin A, Vitale C, Wasik-Szczepanek E, Wróbel T, San Segundo LY, Yassin M, Coscia M, Rambaldi A, Montserrat E, Foà R, Cuneo A, Stamatopoulos K, Ghia P
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
Leukemia 2021 Dec;35(12):3444-3454
IF 11.528

58. Mina R, Falcone AP, Bringhen S, Liberati AM, Pescosta N, Petrucci MT, Ciccone G, Capra A, Patriarca F, Rota-Scalabrini D, Bonello F, Musolino C, Cea M, Zambello R, Tacchetti P, Belotti A, Cellini C, Paris L, Grasso M, Aquino S, De Paoli L, De Sabbata G, Ballanti S, Offidani M, Boccadoro M, Monaco F, Corradini P, Larocca A.
Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial
Blood Cancer J, 2021 Dec 7;11(12):197. doi: 10.1038/s41408-021-00590-5
IF 11.037

59. Boggio E, Gigliotti CL, Moia R, Scotta A, Crespi I, Boggione P, De Paoli L, Deambrogi C, Garzaro M, Vidali M, Chiocchetti A, Stoppa I, Rolla R, Dianzani C, Monge C, Clemente N, Gaidano G, Dianzani U.
Inducible T-cell co-stimulator (ICOS) and ICOS ligand are novel players in the multiplemyeloma microenvironment
Br J Haematol. 2022 Mar;196(6):1369-1380. doi: 10.1111/bjh.17968. Epub 2021 Dec 26.
IF 6.998

60. Molica S, Giannarelli D, Visentin A, Reda G, Sportoletti P, Frustaci AM, Chiarenza A, Ciolli S, Vitale C, Laurenti L, De Paoli L, Murru R, Gentile M, Moia R, Rigolin GM, Levato L, Giordano A, Del Poeta G, Stelitano C, Deodato M, Ielo C, Noto A, Guarente V, Coscia M, Tedeschi A, Gaidano G, Cuneo A, Foa' R, Trentin L, Mauro FR.
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model
Am J Hematol. 2022 May;97(5):E176-E180. doi: 10.1002/ajh.26502. Epub 2022 Feb 25
IF 10.047

61. Ballotta L, Maccaferri M, **De Paoli L**, Orsucci L, Gottardi D, Chiurazzi F, Reda G, Moia R, Cuneo A, Foà R, Marasca R.
Role of chemotherapy in the treatment of chronic lymphocytic leukemia in the era of targeted therapies in Italy. A Campus CLL network report
Hematol Oncol 2023 Feb;41(1):201-204. doi: 10.1002/hon.3047. Epub 2022 Aug 19
IF 4.85

62. Antic D, Milic N, Chatzikonstantinou T, Scarfò L, Otasevic V, Rajovic N, Allsup D, Alonso Cabrero A, Andres M, Baile Gonzales M, Capasso A, Collado R, Cordoba R, Cuéllar-García C, Correa JG, **De Paoli L**, De Paolis MR, Del Poeta G, Dimou M, Doubek M, Efsthathopoulou M, El-Ashwah S, Enrico A, Espinet B, Farina L, Ferrari A, Foglietta M, Lopez-Garcia A, García-Marco JA, García-Serra R, Gentile M, Gimeno E, da Silva MG, Gutwein O, Hakobyan YK, Herishanu Y, Hernández-Rivas JÁ, Herold T, Itchaki G, Jaksic O, Janssens A, Kalashnikova OB, Kalicińska E, Kater AP, Kersting S, Koren-Michowitz M, Labrador J, Lad D, Laurenti L, Fresa A, Levin MD, Mayor Bastida C, Malerba L, Marasca R, Marchetti M, Marquet J, Mihaljevic B, Milosevic I, Mirás

F, Morawska M, Motta M, Munir T, Murru R, Nunes R, Olivieri J, Pavlovsky MA, Piskunova I, Popov VM, Quaglia FM, Quaresmini G, Reda G, Rigolin GM, Shrestha A, Šimkovič M, Smirnova S, Špaček M, Sportoletti P, Stanca O, Stavroyianni N, Te Raa D, Tomic K, Tonino S, Trentin L, Van Der Spek E, van Gelder M, Varettoni M, Visentin A, Vitale C, Vukovic V, Wasik-Szczepanek E, Wróbel T, Segundo LYS, Yassin M, Coscia M, Rambaldi A, Montserrat E, Foà R, Cuneo A, Carrier M, Ghia P, Stamatopoulous k.

Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL

J Hematol Oncol, 2022 Aug 26;15(1):116. doi: 10.1186/s13045-022-01333-0

IF 23.168

Publicazioni in extenso senza Impact Factor

Ripellino P, Comi C, Mula M, Varrasi C, Conconi A, Stecco A, Brustia D, Nasuelli N, Savio K, **De Paoli L**, Cantello R, Gaidano G, Monaco F.

PROGRESSIVE MULTIFOCAL LEUCOENCEPHALOPATHY AFTER AUTOLOGOUS BONE MARROW TRANSPLANTATION: A TREATMENT OPTION.

BMJ Case Reports doi:10.1136/bcr.11.2010.3549, 2011.

Publicazioni in extenso con Impact Factor come collaboratore

Knoebl P, Marco P, Baudo F, Collins P, Huth-Kuhne A, Nemes L, Pellegrini F, Tengborn L, Lévesque H; **EACH2 Registry Contributors**. DEMOGRAPHIC AND CLINICAL DATA IN ACQUIRED HEMOPHILIA A: RESULTS FROM THE EUROPEAN ACQUIRED HAEMOPHILIA REGISTRY (EACH2).

J Thromb Haemost 10 (4): 622-31, 2012

Collins P, Baudo F, Knoebl P, Lévesque H, Nemes L, Pellegrini F, Marco P, Tengborn L, Huth-Kuhne A; **EACH2 Registry Contributors**. IMMUNOSUPPRESSION FOR ACQUIRED HEMOPHILIA: RESULTS FROM THE EUROPEAN ACQUIRED HAEMOPHILIA REGISTRY (EACH2)

Blood, 120 (1): 47-55, 2012

Baudo F, Collins P, Huth-Kuhne A, Knoebl P, Lévesque H, Marco P, Nemes L, Pellegrini F, Tengborn L, Knoebl P; **EACH2 Registry Contributors**. MANAGEMENT OF BLEEDING IN ACQUIRED HEMOPHILIA A: RESULTS FROM THE EUROPEAN ACQUIRED HAEMOPHILIA (EACH2)

Blood, 120 (1): 39-46, 2012

Tengborn L, Baudo F, Huth-Kuhne a, Lévesque H, Marco P, Pellegrini F, Nemes L, Collins P; **EACH2 Registry Contributors**. PREGNANCY – ASSOCIATED ACQUIRED HAEMOPHILIA A: RESULTS FROM THE EUROPEAN ACQUIRED HAEMOPHILIA (EACH2)

BJOG, 119 (12): 1529-37, 2012

Atti di congressi internazionali

Rossi D, Franceschetti S, Vendramin C, Manfroi F, **De Paoli L**, Benevolo G, Gaidano G.
IMMUNODEFICIENCY AND LYMPHOMA: FROM AIDS TO POST-TRANSPLANT.
Haematologica 88-s10: 7-8, 2003

Gaidano G, Rossi D, Cerri M, Franceschetti S, Berra E, Deambrogi C, Vigano F, Cortina F,
De Paoli L, Conconi A, Capello D.
MOLECULAR HISTOGENESIS AND PATHOGENESIS OF HIV-RELATED
LYMPHOMA.
Haematologica 90-s1: 389-391, 2005

Atti di Congressi nazionali

Franceschetti S, Deambrogi C, Cerri M, Riccomagno P, Cresta S, **De Paoli L**, Ramponi A,
Rossi D, Conconi A, capello D, Gaidano G.
DIAGNOSI MOLECOLARE DEI LINFOMI: IMPLICAZIONI CLINICHE.
In Collegio Ghislieri – Centro per la Comunicazione e la Ricerca – Progetto “Progressi in
Biologia e Medicina” – 7° Corso di formazione avanzata “Nanomedicina: dalle
nanostrutture alla terapia personalizzata”. Pavia: Edimes, 2008, pp. 114-120.

Rasi S, Franceschetti S, Bruscazzin A, Spina V, Bruna R, Riccomagno P, **De Paoli L**, Rossi
D, Gaidano G.
ALTERAZIONI GENETICHE E INTERAZIONI CON IL MICROAMBIENTE NEI
LINFOMI MALIGNI.
In Collegio Ghislieri – Centro per la Comunicazione e la Ricerca – Progetto “Progressi in
Biologia e Medicina” – 9° Corso di formazione avanzata “Cellule staminali tumorali: il vero
bersaglio nella cura dei tumori”. Pavia: Edimes, 2010, pp. 140-144.

Spina V, Rasi S, Bruscazzin A, Fangazio M, Deambrogi C, Monti S, Cresta S, Famà R,
Greco M, Ciardullo C, Piranda D, **De Paoli L**, Rossi D, Gaidano G.
BIOLOGICAL AND CLINICAL PREDICTORS OF CHRONIC LYMPHOCYTIC
LEUKEMIA TRANSFORMATION TO RICHTER SYNDROME.
In Collegio Ghislieri – Centro per la Comunicazione e la Ricerca – Progetto “Progressi in
Biologia e Medicina” – 11° Corso di formazione avanzata “Medicina genomica e terapia
personalizzata in ematologia/oncologia”. Pavia: Edimes, 2012, pp. 117-130.

De Paoli L.

Conference insight. IGs Daybreak. The advent of innovation.
L'avvento delle SCIG facilitate in Italia: prime esperienze nel trattamento delle SID
Roma, 28-29 maggio 2015, pp 30-34

Abstract di Congressi internazionali

1. Rossi D, Deambrogi C, Lunghi M, Cerri M, Garbellotto S, Spina V, **De Paoli L**, Riccomagno P, Gloghini A, Lucioni M, Capello D, Paulli M, Carbone A, Gaidano G. ABERRANT METHYLATION OF SHP-1 (SH2-CONTAINING PHOSPHATASE 1) AND SOCS-1 (SUPPRESSOR OF CYTOKINE SIGNALLING 1) GENES IN IMMUNODEFICIENCY-RELATED LYMPHOMAS. *Blood* 108: 675a, 2006
2. Rossi D, Deambrogi C, Capello D, Cerri M, Lunghi M, **De Paoli L**, Parvis G, Saglio G, Gaidano G, Cilloni D. JAK2V617F MUTATION IN LEUKAEMIC TRANSFORMATION OF PHILADELPHIA NEGATIVE CHRONIC MYELOPROLIFERATIVE DISORDERS. *Blood* 108: 1030a, 2006
3. Cerri M, Deambrogi C, Rossi D, Lunghi M, Zigrossi P, Spina V, **De Paoli L**, Riccomagno P, Gloghini A, Lucioni M, Capello D, Paulli M, Carbone A, Gaidano G. ABERRANT METHYLATION OF SHP-1 (SH2-CONTAINING PHOSPHATASE-1) AND SOCS-1 (SUPPRESSOR OF CYTOKINE SIGNALING-1) GENES IN IMMUNODEFICIENCY-RELATED LYMPHOMAS. *Haematologica/Hematol J* 92 (s1): 105, 2007
4. Rossi D, **De Paoli L**, Franceschetti S, Capello D, Vendramin C, Lunghi M, Conconi A, Magnani C, Gaidano G. INCIDENCE AND CLINICAL CHARACTERISTICS OF IMMUNE THROMBOCYTOPENIC PURPURA IN A COHORT OF MONOCLONAL GAMMOPATHY OF UNCERTAIN SIGNIFICANCE. *Haematologica/Hematol J* 92 (s1): 401, 2007
5. Rossi D, Rasi S, Franceschetti S, Capello D, Castelli A, Chiappella A, **De Paoli L**, Ramponi A, Pogliani E, Vitolo U, Conconi A, Gaidano G. THE HOST PHARMACOGENETIC PROFILE IS AN INDEPENDENT PREDICTOR OF OUTCOME AND TOXICITY IN DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH R-CHOP21. *Haematologica/Hematol J* 93 (s1): 159, 2008
6. Rossi D, Lobetti Bodoni C, Genuardi E, Montillo L, Cerri M, Deambrogi C, Drandi D, Ricca I, Rocci A, Boi M, Ferrero S, Capello D, **De Paoli L**, Bergui L, Omedè P, Massaia M, Boccadoro M, Gaidano G, Ladetto M. SHORT TELOMERE LENGTH IS AN INDEPENDENT PREDICTOR OF SURVIVAL, PROGRESSION, RICHTER'S SYNDROME TRANSFORMATION AND RECURRENT INFECTIONS: AN ANALYSIS ON 421 CLL PATIENTS INCLUDING BLINDED VALIDATION ON 230 CASES. *Haematologica/Hematol J* 93 (s1): 162-163, 2008
7. Rossi D, Zucchetto A, Rossi FM, Capello D, Cerri M, Deambrogi C, Cresta S, Rasi S, **De Paoli L**, Lobetti Bodoni C, Bulian P, Del Poeta G, Ladetto M, Gattei V, Gaidano G. CD49d EXPRESSION IS AN INDEPENDENT RISK FACTOR OF PROGRESSIVE DISEASE IN EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA. *Haematologica/Hematol J* 93

(s1): 163, 2008

8. Cerri M, Deambrogi C, Capello D, Cresta S, Rasi S, Sozzi E, **De Paoli L**, Gattei V, Forconi F, Gaidano G, Rossi D. TP53 MUTATIONS AND del17p13 PREDICT SIMILAR OUTCOME AND CHEMOREFRACTORINESS IN CHRONIC LYMPHOCYTIC LEUKEMIA. *Haematologica/Hematol J* 93 (s1): 163-164, 2008
9. Rossi D, Lobetti Bodoni C, Genuardi E, Montillo L, Drandi D, Deambrogi C, Cerri M, Ricca i, Rocci A, Ferrero S, Bernocco E, Capello D, **De Paoli L**, Bergui L, Boi M, Omede P, Massaia M, Tarella C, Passera R, Boccadoro M, Gaidano G. TELOMERE LENGTH IS AN INDEPENDENT PREDICTOR OF SURVIVAL, TREATMENT REQUIREMENT, AND RICHTER'S SYNDROME TRANSFORMATION IN CHRONIC LYMPHOCYTIC LEUKEMIA. *Blood* 112: 1052, 2008
10. Rossi D, Rasi S, Franceschetti S, Capello D, Castelli A, **De Paoli L**, Ramponi A, Chiappella A, Pogliani E. M, Vitolo U, Kwee I, Bretoni F, Conconi A, Gaidano G. THE PHARMACOGENETIC BACKGROUND OF THE HOST IS AN INDEPENDENT PREDICTOR OF OUTCOME AND TOXICITY IN DIFFUSE LARGE B CELL LYMPHOMA TREATED WITH R-CHOP 21. *Blood* 112: 480, 2008
11. Rossi D, Spina V, Cerri M, Deambrogi C, **De Paoli L**, Laurenti L, Maffei R, Forconi F, Canzonieru V, Bertoni F, Martini M, Rasi S, Magni M, Deaglio S, Ladetto M, Cabras A, Nomdedeu J, Besson C, Marasca R, Larocca L, Gattei V, Gaidano G. USAGE OF IGHV4-39 STEREOTYPIC B CELL RECEPTOR IS AN INDEPENDENT RSK FACTOR OF CHRONIC LYMPHOCYTIC LEUKEMIA TRANSFORMATION TO RICHTER SYNDROME. *Blood* 112: 778, 2008
12. Rossi D, Cerri M, Deambrogi C, Sozzi E, Cresta S, Rasi S, **De Paoli L**, Capello D, Gattei V, Forconi F, Lauria F, Gaidano G. THE PROGNOSTIC VALUE OF TP53 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IS INDEPENDENT OF DEL17P13: IMPLICATIONS FOR OVERALL SURVIVAL AND CHEMOREFRACTORINESS. *Blood* 112: 3137, 2008
13. Rossi D, Spina V, Cerri M, Rasi S, Deambrogi C, **De Paoli L**, Laurenti L, Maffei R, Forconi F, Bertoni F, Zucca E, Agostinelli C, Cabras A, Lucioni M, Martini M, Magni M, Deaglio S, Ladetto M, Nomdedeu JF, Besson C, Ramponi A, Canzonieri V, Paulli M, Marasca R, Larocca LM, Carbone A, Pileri S, Gattei V, Gaidano G. STEROTYPED B CELL RECEPTOR AND IGHV4-39 USAGE REPRESENT INDEPENDENT RISK FACTORS OF CHRONIC LYMPHOCYTIC LEUKEMIA TRANSFORMATION TO RICHTER SYNDROME. *Haematologica/The Hematology Journal* 94(s2): 139, 2009
14. Rossi D, Fangazio M, **De Paoli L**, Pinto V, Riccomagno P, Puma A, Ramponi A, Gaidano G. BETA2MICROGLOBULIN IS AN INDEPENDENT PREDICTOR OF PROGRESSION IN ASYMPTOMATIC MULTIPLE MYELOMA. *Haematologica/The Hematology Journal* 94(s2): 156, 2009
15. Forconi F, Puma A, **De Paoli L**, Rasi S, Spina V, Gozzetti A, Tassi M, Sozzi E, Cencini E, Raspadori D, Bertoni F, Gattei V, Lauria F, Gaidano G, Rossi D. THE PROGNOSIS OF CLINICAL MONOCLONAL B CELL LYMPHOCYTOSIS DIFFERS FROM PROGNOSIS OF RAI 0 CHRONIC LYMPHOCYTIC LEUKEMIA AND IS RECAPITUALTED BY BIOLOGICAL RISK FACTORS. *Haematologica/The Hematology*

16. Rossi D, Rasi S, Fabbri A, Forconi F, Fangazio M, Bruscazzin A, Franceschetti S, **De Paoli L**, Puma A, Bruna R, Chiappella A, Pogliani EM, Lauria F, Vitolo U, Gaidano G. THE HOST GENETIC BACKGROUND OF DNA REPAIR MECHANISMS REPRESENTS AN INDEPENDENT PREDICTOR OF PROGRESSION AND SURVIVAL IN DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH R-CHOP. *Blood* 114: 442, 2009
17. Rossi D, Fangazio M, **De Paoli L**, Pinto V, Riccomagno P, Puma A, Ramponi A, Monga G, Gaidano G. BETA-2-MICROGLOBULIN IS AN INDEPENDENT PREDICTOR OF PROGRESSION IN ASYMPTOMATIC MULTIPLE MYELOMA. *Blood* 114: 1796, 2009
18. Gozzetti A, Oliva S, Gentilini F, Marchini E, Petrucci MT, Patriarca F, Petrucci A, Giaccone L, Zamagni E, Genuardi M, Cavo M, Palumbo A, Rossi D, Offidani M, Cerase A, **De Paoli L**, Floridia M, Mele G, Galli M, Beretta S, Di Raimondo F, Vallone R, Lauria F. CENTRAL NERVOUS SYSTEM AND INTRACRANIAL MYELOMA: A RETROSPECTIVE ITALIAN MULTICENTER STUDY. *Blood* 114: 1882, 2009
19. Rossi D, Rasi S, Fabbri A, Forconi F, Bruscazzin A, Di Rocco A, Fangazio M, Franceschetti S, **De Paoli L**, Bruna R, Chiappella A, Pogliani E, Lauria F, Vitolo U, Hohaus S, Martelli M, Foà R, Gaidano G. A GENETIC VARIANT OF MLH1, A GENE INVOLVED IN DNA MISMATCH REPAIR, IS AN INDEPENDENT PREDICTOR OF OVERALL SURVIVAL IN DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH R-CHOP. *Haematologica/Hematol J* 95 (s2): 237, 2010
20. Palumbo A, Falco P, Benevolo G, Rossi D, Carella AM, Guglielmelli T, Rocci A, **De Paoli L**, Grasso M, Mosca Siez ML, Piro E, Caltagirone S, Gay F, Cavallo F, Gaidano G, Boccadoro M. A MULTICENTER, OPEN LABEL STUDY OF ORAL LENALIDOMIDE AND PREDNISONE (RP) FOLLOWED BY ORAL LENALIDOMIDE MELPHALAN AND PREDNISONE (MPR) AND ORAL LENALIDOMIDE MAINTENANCE IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS. *Blood* 116: 1940, 2010
21. Rossi D, Rasi S, Di Rocco A, Fabbri A, Forconi F, Bruscazzin A, Franceschetti S, Fangazio M, **De Paoli L**, Bruna R, Capello D, Chiappella A, Lobetti Bodoni C, Giachelia M, Tisi MC, Pogliani EM, Lauria F, Ladetto M, Hohaus S, Martelli M, Vitolo U, Foà R, Gaidano G. THE GENOTYPE OF MLH1 IS AN INDEPENDENT PREDICTOR OF OUTCOME IN DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH R-CHOP: A TRAINING-VALIDATION STUDY. *Blood* 116: 992, 2010
22. Bringhen S, Falco P, Rossi D, Guglielmelli T, Rocci A, **De Paoli L**, Grasso M, Benevolo G, Mosca Siez ML, Piro E, Ruggeri M, Palladino C, Genuardi M, Carella A, Gaidano G, Boccadoro M, Palumbo A. A MULTICENTER, OPEN LABEL STUDY OF LENALIDOMIDE AND PREDNISONE (RP) FOLLOWED BY LENALIDOMIDE, MELPHALAN AND PREDNISONE (MPR) IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS. *Haematologica/Hematol J* 96 (s2): 121, 2011
23. Rossi D, Rasi S, Fabbri G, Spina V, Fangazio M, Forconi F, Marasca R, Laurenti L, Bruscazzin A, Cerri M, Monti S, Cresta S, Famà R, **De Paoli L**, Bulian P, Gattei V, Guarini A, Deaglio S, Capello D, Rabadan R, Pasqualucci L, Dalla-Favera R, Foà R, Gaidano G. MUTATIONS OF NOTCH1 ARE AN INDEPENDENT PREDICTOR OF SURVIVAL IN

CHRONIC LYMPHOCYTIC LEUKEMIA. *Blood* 118: 283, 2011

24. Tedeschi A, Rossi D, Coscia M, Vismara E, Belsito Petrizzi V, Orlandi E, Cascavilla N, Scarfò L, Motta M, Vitale C, Ricci F, **De Paoli L**, D'Arco AM, Gallamini A, Gaidano G, Morra E, Massaia M, Montillo M. FINAL REPORT OF BENDAMUSTINE AND ALEMTUZUMAB (BEN CAM) COMBINATION IN RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA. *Blood* 120: 2898, 2012
25. Zallio F, Baraldi A, Montefusco V, Cavallo F, **De Paoli L**, Minetto P, Catania G, Rapetti M, Gaidano G, salvi F, Levis A. SUCCESSFUL STEM CELL RE-MOBILIZATION AND HARVEST IN PATIENTS WITH MULTIPLE MYELOMA RELAPSED AFTER A PREVIOUS MYELOABLATIVE AUTOLOGOUS TRANSPLANT. *Haematologica/Hematol J* 98 (s1): 188, 2013
26. Bringhen S, Cerrato C, Petrucci MT, Genuardi M, Gentilini F, Conticello C, Oliva S, Pantani L, Offidani M, Palladino C, Benevolo G, Montefusco V, Astolfi M, Villani O, Siniscalchi A, Rocci A, **De Paoli L**, Boccadoro M, Sonneveld P, Palumbo A. A PHASE II STUDY WITH CARFILZOMIB , CYCLOPHOSPHAMIDE AND DEXAMETHASONE (CCd) FOR NEWLY DIAGNOSED MULTIPLE MYELOMA. *Blood* 122: 685, 2013
27. Montillo M, Rossi D, Motta M, Quaresmini G, Rossi M, Coscia M, Anastasia A, Rossini F, Cortelezzi A, Nador G, Scarfò L, Cairoli R, Dal Ceggio D, **De Paoli L**, Morra E, Rambaldi A, Orlandi E, Massaia M, Tedeschi A. A PHASE II MULTI-CENTER TRIAL OF PENTOSTATIN PLUS CYCLOPHOSPHAMIDE WITH OFATUMUMAB (PCO) IN OLDER PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS. *Blood* 122: 4177, 2013
28. Cerrato C, Oliva S, Petrucci MT, Caraffa P, Bozzoli C, Finsinger P, Larocca A, De Rosa L, **De Paoli L**, Montefusco V, Saraci E, Villani O, Carella AM, Benevolo G, Morabito F, Liberati AM, Derudas D, Boccadoro M, Sonneveld P, Palumbo A. EFFICACY AND SAFETY OF THREE SUBCUTANEOUS BORTEZOMIB COMBINATIONS IN ELDERLY, NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS. *Haematologica/Hematol J* 99 (s1): 4252, 2014
29. Montillo M, Rossi D, Motta M, Quaresmini G, Rossi M, Coscia M, Anastasia A, Rossini F, Cortellezzi A, Nador G, Scarfò L, Cairoli R, Frustaci AM, Dal Ceggio D, Picardi P, **De Paoli L**, Orlandi E, Rambaldi A, Morra E, Massaia M, Tedeschi A. A PHASE II MULTI-CENTER TRIAL OF PENTOSTATIN PLUS CYCLOPHOSPHAMIDE WITH OFATUMUMAB (PCO) IN OLDER PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS. *Haematologica/Hematol J* 99 (s1): 4238, 2014

Abstract di Congressi nazionali

30. Deambrogi C, Barbieri C, Cerri M, Garbellotto S, Spina V, **De Paoli L**, Rossi D, Gloghini A, Lucioni M, Capello D, Paulli M, Carbone A, Gaidano G, Lunghi M. ABERRANT METHYLATION OF SOCS-1 (SUPPRESSOR OF CYTOKINE SIGNALING-1) AND SHP-1 (SH2-CONTAINING PHOSPHATASE-1) GENES IN IMMUNODEFICIENCY-RELATED LYMPHOMAS. *Haematologica/The Hematology Journal* 91 (Suppl. 3): 41, 2006

31. Rossi D, Berra E, Cerri M, Deambrogi C, Barbieri C, Franceschetti S, Conconi A, **De Paoli L**, Paulli M, Matolcsy A, Pasqualucci L, Capello D, Gaidano G. ABERRANT SOMATIC HYPERMUTATION IS INVOLVED IN TRANSFORMATION OF FOLLICULAR LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA TO DIFFUSE LARGE B-CELL LYMPHOMA. *Haematologica/The Hematology Journal* 91 (Suppl. 3): 47, 2006
32. Rossi F, Marcheselli L, Rossi D, Callea V, Guffanti A, Federico V, De Muro M, Baraldi A, Musto P, Bacigalupo A, Gaidano G, Petrucci MT, Goldaniga M, **De Paoli L**, Baldini L. LOW RISK IgG MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (MGUS): PROPOSAL AND VALIDATION OF A PROGNOSTIC SCORING SYSTEM. *Haematologica/The Hematology Journal* 92 (Suppl. 3): 135, 2007
33. Rossi D, Deambrogi C, Cerri M, **De Paoli L**, Franceschetti S, Capello D, Vendramin C, Lunghi M, Conconi A, Gaidano G. LE LESIONI MOLECOLARI DEI GENI SHP-1, SOCS-1 E SOCS-3 RAPPRESENTANO UN MECCANISMO PATOGENETICO FREQUENTE NELLE MALATTIE MIELOPROLIFERATIVE CRONICHE PHIOLADELPHIA NEGATIVE. *Internal and Emergency Medicine* 2: S9, 2007
34. Rossi D, **De Paoli L**, Cerri M, Deambrogi C, Vendramin C, Franceschetti S, Lunghi M, Conconi A, Capello D, Ramponi A, Gaidano G. VARIABILI CLINICO-BIOLOGICHE PREDITTIVE DI TRASFORMAZIONE DA LEUCEMIA LINFATICA CRONICA A LINFOMA DIFFUSO A GRANDI CELLULE B (SINDROME DI RICHTER). *Internal and Emergency Medicine* 2: S10-S11, 2007
35. Rossi D, **De Paoli L**, Franceschetti S, Capello D, Vendramin C, Lunghi M, Conconi A, Magnani C, Gaidano G. PREVALENZA E CARATTERISTICHE CLINICHE DELLA PORPORA TROMBOCITOPENICA IMMUNOLOGICA ASSOCIATA A GAMMOPATIA MONOCLONALE DI SIGNIFICATO INDETERMINATO (MGUS). *Internal and Emergency Medicine* 2: S48-S49, 2007
36. Rasi S, Rossi D, Franceschetti S, Capello D, Castelli A, Chiappella A, **De Paoli L**, Ramponi A, Pogliani E, Vitolo U, Conconi A, Gaidano G. THE PHARMACOGENETIC BACKGROUND OF THE HOST IS AN INDEPENDENT PREDICTOR OF OUTCOME AND TOXICITY IN DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH R-CHOP21. *Haematologica/The Hematology Journal* 93 (Suppl. 2): 32, 2008
37. Rossi D, Cerri M, Forconi F, Deambrogi C, Sozzi E, Cresta S, Rasi S, Tassi M, **De Paoli L**, Raspadori D, Capello D, Gattei V, Lauria F, Gaidano G. TP53 MUTATIONS AND del17p13 PREDICT SIMILAR OUTCOME AND CHEMOREFRACTORINESS IN CHRONIC LYMPHOCYTIC LEUKEMIA. *Haematologica/The Hematology Journal* 93 (Suppl. 2): 91-92, 2008
38. Rossi D, Lobetti Bodoni C, Genuardi E, Montillo L, Cerri M, Deambrogi C, Drandi D, Ricca I, Rocci A, Boi M, Ferrero S, Capello D, **De Paoli L**, Bergui L, Omedè P, Massaia M, Boccadoro M, Gaidano G, Ladetto M. SHORT TELOMERE LENGTH IS AN INDEPENDENT PREDICTOR OF SURVIVAL, PROGRESSION, RICHTER'S SYNDROME TRANSFORMATION AND RECURRENT INFECTIONS: AN ANALYSIS ON 421 CLL PATIENTS INCLUDING BLINDED VALIDATION ON 230 CASES. *Haematologica/The Hematology Journal* 93 (Suppl. 2): 92, 2008

39. Deambrogi C, Cresta S, Cerri M, **De Paoli L**, Capello D, Gaidano G, Rossi D. BCL3 TRANSLOCATION IS A FREQUENT AND SELECTIVE EVENT IN CHRONIC LYMPHOCYTIC LEUKEMIA CARRYING +12. *Haematologica/The Hematology Journal* 93 (Suppl. 2): 92, 2008
40. Rossi D, Zucchetto A, Rossi FM, Capello D, Cerri M, Deambrogi C, Cresta S, Rasi S, **De Paoli L**, Lobetti Bodoni C, Bulian P, Del Poeta G, Ladetto M, Gattei V, Gaidano G. CD49d EXPRESSION IS AN INDEPENDENT PREDICTOR OF PROGRESSIVE DISEASE IN BINET A CHRONIC LYMPHOCYTIC LEUKEMIA. *Haematologica/The Hematology Journal* 93 (Suppl. 2): 93, 2008
41. Rossi D, Cerri M, Deambrogi C, Capello D, Cresta S, Rasi S, Sozzi E, **De Paoli L**, Gattei V, Forconi F, Lauria F, Gaidano G. IL SIGNIFICATO PROGNOSTICO DELLE MUTAZIONI DI TP53 NELLA LEUCEMIA LINFATICA CRONICA E' INDIPENDENTE DALLA DELEZIONE 17p13: IMPLICAZIONI PER LA PROGNOSE E LA CHEMIORREFRATTARIETA' DELLA MALATTIA. *Internal and Emergency Medicine*, 3: S19-S20, 2008
42. Franceschetti S, Rossi D, Rasi S, Capello D, Castelli A, Chiappella A, **De Paoli L**, Ramponi A, Pogliani E, Vitolo U, Conconi A, Gaidano G. IL PROFILO FARMACOGENETICO DELL'OSPITE E' UN PREDITTORE INDIPENDENTE DI OUTCOME E DI TOSSICITA' NEL LINFOMA DIFFUSO A GRANDI CELLULE B TRATTATO CON R-CHOP21. *Internal and Emergency Medicine*, 3: S20, 2008
43. Rossi D, Zucchetto A, Rossi FM, Capello D, Cerri M, Deambrogi C, Cresta S, Rasi S, **De Paoli L**, Lobetti Bodoni C, Bulian P, Del Poeta G, Ladetto M, Gattei V, Gaidano G. L'ESPRESSIONE DI CD49d E' UN PREDITTORE INDIPENDENTE DI PROGRESSIONE DI MALATTIA NELLA LEUCEMIA LINFATICA CRONICA IN STADIO BINET A. *Internal and Emergency Medicine*, 3: S21, 2008
44. Rossi D, Lobetti Bodoni C, Genuardi E, Montillo L, Cerri M, Deambrogi C, Drandi D, Ricca I, Rocci A, Capello D, **De Paoli L**, Bergui L, Omedè P, Massaia M, Boccadoro M, Ladetto M, Gaidano G. LA LUNGHEZZA DEL TELOMERO E' UN FATTORE DI RISCHIO INDIPENDENTE DI MORTE, PROGRESSIONE E TRASFORMAZIONE A SINDROME DI RICHTER: ANALISI SU 401 CASI DI LEUCEMIA LINFATICA CRONICA. *Internal and Emergency Medicine*, 3: S25-26, 2008
45. Rossi D, Spina V, Cerri M, Rasi S, Deambrogi C, **De Paoli L**, Laurenti I, Maffei R, Forconi F, Bertoni F, Zucca E, Agostinelli C, Cabras A, Ludioni M, Martini M, Magni M, Deaglio S, Ladetto M, Nomdedeu J.F, Besson C, Canzonieri V, Palli M, Marasca R, Larocca L.M, Carbone A, Pileri S.A, Gattei V, Gaidano G. STEROTYPIC B-CELL RECEPTOR AND IGHV4-39 USAGE REPRESENT INDEPENDENT RISK FACTORS OF CHRONIC LYMPHOCYTIC TRANSFORMATION TO RICHTER SYNDROME. *Haematologica/The Hematology Journal* 94 (Suppl. 4): 30, 2009
46. Fangazio M, **De Paoli L**, Pinto V, Riccomagno P, Puma A, Ramponi A, Gaidano G, Rossi D. BETA-2 MICROGLOBULIN IS AN INDEPENDENT PREDICTOR OF PROGRESSION IN ASYMPTOMATIC MULTIPLE MYELOMA. *Haematologica/The Hematology Journal* 94 (Suppl. 4): 85, 2009

47. Rossi F, Petrucci M.T, Guffanti A, Marcheselli L, Rossi D, Callea V, Vincenzo F, De Muro M, Baraldi A, Villani O, Musto P, Bacigalupo A, Gaidano G, Avvisati G, Goldaniga M, **De Paoli L**, Baldini L. PROGNOSTIC SCORING SYSTEMS FOR IGG AND IGA MONOCLONALGAMMOPATHIES OF UNDETERMINED SIGNIFICANCE. *Haematologica/The Hematology Journal* 94 (Suppl. 4): 88, 2009
48. Forconi F, Puma a, **De Paoli L**, Rasi S, Spina V, Gozzetti A, Tassi M, Sozzi E, Cencini E, Raspadori D, Bretoni F, Gattei V, Lauria F, Gaidano G, Rossi D. THE PROGNOSIS OF CLINICAL MONOCLONAL B CELL LYMPHOCYTOSIS DIFFERS FROM PROGNOSIS OF RAI 0 CHRONIC LYMPHOCYTIC LEUKAEMIA AND IS RECAPITULATED BY BIOLOGICAL RISK FACTORS. *Haematologica/The Hematology Journal* 94 (Suppl. 4): 187, 2009
49. Rasi S, Fabbri A, Forconi F, Bruscazzin A, Di Rocco A, Fangazio M, Lobetti, Bodoni C, Franceschetti S, **De Paoli L**, Bruna R, Chiappella A, Pogliani EM, Ladetto M, Lauria F, Vitolo U, Hohaus S, Martelli M, Foà R, Gaidano G, Rossi D. A GENETIC VARIANT OF MLH1, A GENE INVOLVED IN DNA MISMATCH REPAIR, IS AN INDEPENDENT PREDICTOR OF SURVIVAL IN DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH R-CHOP. *Haematologica/The Hematology Journal* 95 (Suppl. 3): 26-27, 2010
50. Deambroggi C, Cresta S, Monti S, **De Paoli L**, Fangazio M, Giardini I, Bernasconi P, Gaidano G, Rossi D. BCL3 TRANSLOCATION IN CLL WITH TYPICAL PHENOTYPE: ASSESSMENT OF FREQUENCY, ASSOCIATION WITH CYTOGENETIC SUBGROUPS AND PROGNOSTIC SIGNIFICANCE. *Haematologica/The Hematology Journal* 95 (Suppl. 3): 90, 2010
51. Falco P, Benevolo G, Cavallo F, Gaidano G, Carella AM, Guglielmelli T, Rocci A, Rossi D, Grasso M, Mosca Siez ML, Piro E, Lupo B, **De Paoli L**, Boccadoro M, Palumbo A. ORAL REVLIMID AND PREDNISONE FOLLOWED BY ORAL REVLIMID, MELPHALAN AND PREDNISONE IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS: A MULTICENTER, OPEN LABEL STUDY. *Haematologica/The Hematology Journal* 95 (Suppl. 3): 103-104, 2010
52. Falco P, Larocca A, Rossi D, Guglielmelli T, Palladino C, **De Paoli L**, Grasso M, Benevolo G, Mosca Siez ML, Piro E, Saraci E, Genuardi M, Carella AM, Gaidano G, Boccadoro M, Plumbo A. MULTICETRER PHASE II STUDY OF LENALIDOMIDE AND PREDNISONE (RP) FOLLOWED BY LENALIDOMIDE, MELPHALAN, PREDNISONE (MPR) IN NEWLY DIAGNOSED ELDERLY UNFIT MULTIPLE MYELOMA PATIENTS. *Haematologica/The Hematology Journal* 96 (Suppl. 3): 48, 2011
53. Rasi S, Bruscazzin A, Rinaldi A, Cresta S, Fangazio M, **De Paoli L**, Monti S, Gargiulo E, Foà R, Bertoni F, Gaidano G, Rossi D. SALIVA IS A RELIABLE AND PRACTICAL SOURCE OF GERMLINE DNA FOR GENOME-WIDE STUDIES IN CHRONIC LYMPHOCYTIC LEUKEMIA. *Haematologica/The Hematology Journal* 96 (Suppl. 3): 139, 2011
54. Cerrato C, Bringhen S, Cavallo F, Petrucci MT, **De Paoli L**, Siniscalchi A, Genuardi M, Villani O, Offidani M, Magarotto V, Benevolo G, Corradini P, Ruggeri M, Pantani I, Conticello C, Finsinger P, sonneveld P, Boccadoro M, Palumbo A. PHASE II STUDY OF EFFICACY AND SAFETY OF THE COMBINATION CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (CCD) IN NEWLY

DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS: PRELIMINARY RESULTS. *Haematologica/The Hematology Journal* 98 (Suppl. 3): 11, 2013

55. Bringhen S, Larocca A, Conticello C, Liberati AM, **De Paoli L**, Falcone AP, Lupparelli G, Buttignol S, Finsinger P, Montefusco V, Offidani M, Benevolo G, Siniscalchi A, Ria R, Zambello R, Carella AM, Pezzatti S, Galli M, Catalano L, Vincelli ID, Grasso M, Guglielmelli T, Cangialosi C, Pescosta N, Rossi G, Musolino C, Musto P, Ciccone G, Boccadoro M, Palumbo A. META-ANALYSIS OF 6383 INDIVIDUAL PATIENT DATA: SECOND PRIMARY MALIGNANCIES (SPM) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS ACCORDING TO LENALIDOMIDE EXPOSURE. *Haematologica/The Hematology Journal* 98 (Suppl. 3): 49-50, 2013
56. Mina R, Larocca A, Montefusco V, Gay F, **De Paoli L**, Crippa C, Cavallo F, Galli M, Marcatti M, Moschetti A, Giuliani N, Guglielmelli T, Rota-Scalabrini D, Caltagirone S, Santagostino A, Baldi I, Spriano M, Boccadoro M, Palumbo A. A PHASE I/II, MULTI-CENTER, OPEN LABEL STUDY OF POMALIDOMIDE, CYCLOPHOSPHAMIDE AND PREDNISON (PCP) IN PATIENTS WITH MULTIPLE MYELOMA RELAPSED AND/OR REFRACTORY TO LENALIDOMIDE. *Haematologica/The Hematology Journal* 98 (Suppl. 3): 75, 2013
57. Ciardullo C, Rasi S, Spina V, Cerri M, Cresta S, De Paoli L, Guarini A, Rossi D, Foà R, Gaidano G. THE IMPACT OF NEW TECHNOLOGIES ON THE UNDERSTANDING OF CHRONIC LYMPHOCYTIC LEUKEMIA. *Haematologica/The Hematology Journal* 98 (Suppl. 3): 229, 2013